Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo for lung cancer shows promise but study cut short

NCT ID NCT04984811

Disease control Sponsor: NeoImmuneTech Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of two drugs—NT-I7 and atezolizumab—in people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors. However, the study was stopped early and only enrolled 33 out of a planned 83 participants, so the results are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
efineptakin alfa (NT-I7) plus atezolizumab (Tecentriq)
What this could lead to
If it works, this combination could improve tumor shrinkage rates in advanced lung cancer patients who have not had prior treatment.
What could go wrong
The trial was terminated early with only 33 participants, so results are limited. It is a small, single-arm study with no comparison group, making it hard to know if the combination is truly better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

33 people

The number who actually took part.

Started

Nov 2021

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have histologically or cytologically confirmed metastatic or locally advanced NSCLC, and have not received prior systemic therapy. Subjects with locally advanced disease must have Stage III NSCLC and are not candidates for surgical resection or definitive chemoradiation * Tumor PD-L1 expression (TPS≥1%) as determined by PD-L1 22C3 immunohistochemistry local or central assay. * Have measurable disease * Agree to provide screening biopsy (or archival tissue) at screening to assess PD-L1 * ECOG 0-1 * Adequate hematologic and end organ function Exclusion Criteria: * Prior systemic anti-cancer therapy * NSCLC with EGFR, or ALK, or BRAF or ROS or RED or other genomic tumor aberrations which have available therapy * Prior radiotherapy within 2 weeks of start of study treatment * Known active CNS metastasis or carcinomatous meningitis * Severe reactions to mAbs or IV immunoglobulin preparations * Autoimmune disease history in past two years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung Non small cell lung carcinoma Non-small cell lung cancer Nonsmall cell lung cancer

Contacts and locations

Locations

  • BRCR Medical Center

    Plantation, Florida, 33322, United States

  • East Carolina University

    Greenville, North Carolina, 27834, United States

  • Eastern CT Hematology & Oncology Associates

    Norwich, Connecticut, 06360, United States

  • Florida Cancer Specialists - East Research Office

    West Palm Beach, Florida, 33401, United States

  • Florida Cancer Specialists - North Research Office

    St. Petersburg, Florida, 33705, United States

  • Florida Cancer Specialists - South Research Office

    Fort Myers, Florida, 33916, United States

  • Goshen Center for Cancer Care

    Goshen, Indiana, 46526, United States

  • MaineHealth Cancer Care

    South Portland, Maine, 04106, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40217, United States

  • OHSU Knight Cancer Institute

    Portland, Oregon, 97239, United States

  • Pikeville Medical Center, Inc.

    Pikeville, Kentucky, 41501, United States

  • Renovatio Clinical - El Paso

    El Paso, Texas, 79915, United States

  • Renovatio Clinical - The Woodlands

    The Woodlands, Texas, 77380, United States

  • Summit Health Medical Center

    Florham Park, New Jersey, 07932, United States

  • TOI Clinical Research

    Cerritos, California, 90703, United States

  • Tennessee Oncology - Chattanooga

    Chattanooga, Tennessee, 37404, United States

  • Tennessee Oncology - Nashville

    Nashville, Tennessee, 37203, United States

  • Thompson Cancer Survival Center

    Knoxville, Tennessee, 37916, United States

  • TidalHealth Peninsula Regional, Inc.

    Salisbury, Maryland, 21801, United States

  • University Cancer and Blood Center

    Athens, Georgia, 30607, United States

  • University of South Alabama

    Mobile, Alabama, 36604, United States

  • Zangmeister Cancer Center

    Columbus, Ohio, 43219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.